Industry

DUBLIN–(BUSINESS WIRE)–The “Doxorubicin Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Drug Formulation, Application, and Distribution Channel” report has been added to ResearchAndMarkets.com’s offering. The global doxorubicin market is projected to reach US$ 1,983.40 million by 2028 from US$ 1,390.64 million in 2022; it is expected to register a CAGR of 6.1% … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Cardiac Markers Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive information about the Cardiac Markers Rapid Tests & POC pipeline products with comparative analysis of the products at various … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Biostimulants Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product, Mode of Application, and Crop Type” report has been added to ResearchAndMarkets.com’s offering. The biostimulants market is expected to grow from US$ 3,112.49 million in 2022 to US$ 5,796.94 million by 2028; it is estimated to grow at a CAGR … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Aseptic Processing Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global aseptic processing market is expected to grow from $68.62 billion in 2021 to $72.40 billion in 2022 at a compound annual growth rate (CAGR) of 5.52%. The aseptic processing market is expected to grow to $87.38 billion in … [Read more…]

Tenalisib (RP6530, selective dual PI3K d/γ inhibitor with additional SIK3 inhibitory activity) showed encouraging results with a clinical benefit rate (CBR) of 57.5% from an ongoing phase II trial in patients with locally advanced or metastatic HR+/HER2- breast cancer (mBC) RP12146, Rhizen’s next generation PARP1/2 inhibitor concludes dose escalation phase with a favorable safety profile … [Read more…]

PORTLAND, Ore.–(BUSINESS WIRE)–Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, today announced that the first patient has been dosed in a phase 2 clinical trial (NCT number: NCT05436652) of prednisolone in combination with SPI-62, Sparrow’s potent and selective investigational HSD-1 inhibitor, for the … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969) announced today that the first patient was dosed in the phase II registrational trial (Registry number: CTR20221519) of tafasitamab in combination with lenalidomide for adult patients in China who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and are not eligible for autologous stem cell transplantation (ASCT). Dr. Jasmine … [Read more…]

Final Data From One of the Largest Multi-Cancer Early Detection Studies in an Intended Use Population MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced final results from the interventional PATHFINDER study will be presented at the European Society for Medical Oncology … [Read more…]

SAN FRANCISCO–(BUSINESS WIRE)–Radiology startup Chiasm has developed a platform that transforms the imaging diagnostic process of healthcare. Chiasm is designed to bridge the imaging gap for patients, giving full control of information to those who need it most. For imaging centers, it’s an online booking platform that allows patients to schedule appointments and follow ups … [Read more…]

OTTAWA, Ontario–(BUSINESS WIRE)–CUPE, Canada’s largest union, is appalled at the Canadian Blood Services (CBS) decision to sign a secret plasma privatization deal that puts our entire blood system at risk. The 15-year contract with global plasma corporation, Grifols, will allow the corporation to develop a US-style paid plasma system in Canada and give privatization another … [Read more…]